Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a p.